WARSAW, Ind. , Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ( NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 8:15 a.m. PT ( 11:15 a.m. ET ). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at... Read More

WARSAW, Ind. , Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc . (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30,... Read More

New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind. , Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral... Read More

A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind. , Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona ® SoluTion™ Porous Plasma Spray (PPS ® ) Femur, a total knee implant component offering an alternative for patients with... Read More

WARSAW, Ind. , Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford ® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for... Read More

WARSAW, Ind. , Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024 , with a fireside chat at 8:45 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . The webcast... Read More

WARSAW, Ind., and ZURICH , Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing... Read More

Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind. , Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger , who will take on the newly established role... Read More

WARSAW, Ind. , Nov. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Jefferies London Healthcare Conference on November 19, 2024 , with a fireside chat at 11:00 a.m. GMT ( 6:00 a.m. ET ). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at... Read More

Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency 1 basis Third quarter diluted earnings per share were $1.23 ; adjusted 1 diluted earnings per share were $1.74 Company updates 2024 financial guidance, reducing and narrowing range for full year outlook WARSAW, Ind. , Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the... Read More

Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI ® and HAMMR™ Automated Hip Impaction System WARSAW, Ind. , Oct. 28, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual... Read More

DURHAM, N.C. and WARSAW, Ind. , June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will... Read More

WARSAW, Ind. , Dec. 14, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of its Executive Management Team are scheduled to present at the Goldman Sachs CEOs Unscripted Conference on Thursday, January 5, 2023 , at 11:25 a.m. ET and at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 , at 3:45 p.m. PT / 6:45... Read More